Moderna Just Cleared the Bar That No mRNA Cancer Therapy Ever Had

A record fourth quarter, a 53% jump in net income and a dividend increase sent $NSSC up more

A personalized cancer vaccine built from a patient’s own tumor beat Keytruda alone in a late-stage melanoma trial

Every so often a beaten-down micro-cap wakes up all at once — and the tape tells you something

In 2026, the fastest-moving corner of defense isn’t jets or tanks — it’s autonomous systems. And one of

A company that sells software to cardiologists grew revenue 48% and raised its full-year outlook for the second

A 49% cash premium sent $ARX up almost 45% before the bell — and yet the buyout price